fasudil has been researched along with Diabetic Retinopathy in 6 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Diabetic Retinopathy: Disease of the RETINA as a complication of DIABETES MELLITUS. It is characterized by the progressive microvascular complications, such as ANEURYSM, interretinal EDEMA, and intraocular PATHOLOGIC NEOVASCULARIZATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response." | 8.12 | Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022) |
| "This study evaluates the effect of intravitreal injection of a Rho-associated protein kinase (ROCK) inhibitor, fasudil, on diabetic macular edema (DME) with an unfavorable response." | 4.12 | Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response. ( Machida, S; Muto, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Muto, T | 1 |
| Machida, S | 1 |
| Rothschild, PR | 1 |
| Salah, S | 1 |
| Berdugo, M | 1 |
| Gélizé, E | 1 |
| Delaunay, K | 1 |
| Naud, MC | 1 |
| Klein, C | 1 |
| Moulin, A | 1 |
| Savoldelli, M | 1 |
| Bergin, C | 1 |
| Jeanny, JC | 1 |
| Jonet, L | 1 |
| Arsenijevic, Y | 1 |
| Behar-Cohen, F | 1 |
| Crisanti, P | 1 |
| Ahmadieh, H | 2 |
| Nourinia, R | 2 |
| Hafezi-Moghadam, A | 2 |
| Sabbaghi, H | 1 |
| Nakao, S | 1 |
| Zandi, S | 1 |
| Yaseri, M | 1 |
| Tofighi, Z | 1 |
| Akbarian, S | 1 |
| Kita, T | 1 |
| Arita, R | 1 |
2 reviews available for fasudil and Diabetic Retinopathy
| Article | Year |
|---|---|
[Molecular mechanisms of preretinal membrane contraction in proliferative vitreoretinal diseases and ROCK as a therapeutic target].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Retinopathy; Molecular Targeted The | 2010 |
[Mechanism of diabetes-induced microvascular damage and therapeutic potential of ROCK inhibition].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Angiopathies; Diabetic Retinopathy; | 2011 |
1 trial available for fasudil and Diabetic Retinopathy
| Article | Year |
|---|---|
Intravitreal injection of a Rho-kinase inhibitor (fasudil) combined with bevacizumab versus bevacizumab monotherapy for diabetic macular oedema: a pilot randomised clinical trial.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Aged; Angiogenesis Inhibitors; Bevacizumab; Di | 2019 |
3 other studies available for fasudil and Diabetic Retinopathy
| Article | Year |
|---|---|
Intravitreal Fasudil for Treatment of Diabetic Macular Edema with an Unfavorable Response.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Diabetes Mellitus; Diabetic Retinopathy; Humans | 2022 |
ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Animals; Biomarkers; Case-Control Studies; Cyto | 2017 |
Intravitreal fasudil combined with bevacizumab for persistent diabetic macular edema: a novel treatment.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal | 2013 |